Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

On March 19, 2026, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) saw its price target raised by Wells Fargo from $515 to $550. The firm’s analyst kept an Overweight rating on the shares. Wells Fargo anticipates a threefold growth in the market for the generalized Myasthenia Gravis (gMG), reaching $20 billion globally by 2036. Analysts cite new drugs and mechanisms, such as CD20, BAFF/APRILs, and next-generation complement inhibitors, as significant drivers of growth. The firm identifies Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Amgen (AMGN), and Regeneron (REGN) as the key beneficiaries of this growth, while expressing a notable belief in an upside to current Wall Street estimates.

In a separate event, on March 18, 2026, Maxim upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Buy and maintained a $575 price target. According to the firm, Povetacicept has the potential to be a blockbuster with “pipeline-in-a-product” capabilities. The analyst further noted that, alongside Journavx and Casgevy, the company has three products that provide crucial diversification beyond its cystic fibrosis franchise.

Founded in 1989, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company. Based in Massachusetts, the company develops and commercializes therapies for serious diseases, with a primary focus on cystic fibrosis and genetic disorders.

While we acknowledge the risk and potential of VRTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Space Exploration Stocks to Buy According to Analysts and 10 Best Diagnostics and Research Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.